Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study

BACKGROUND: ATP acting via P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor antagonist, in adults with RCC attending specialist...

Descripción completa

Detalles Bibliográficos
Autores principales: Morice, Alyn, Smith, Jaclyn A., McGarvey, Lorcan, Birring, Surinder S., Parker, Sean M., Turner, Alice, Hummel, Thomas, Gashaw, Isabella, Fels, Lueder, Klein, Stefan, Francke, Klaus, Friedrich, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607926/
https://www.ncbi.nlm.nih.gov/pubmed/33986030
http://dx.doi.org/10.1183/13993003.04240-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607926/
https://www.ncbi.nlm.nih.gov/pubmed/33986030
http://dx.doi.org/10.1183/13993003.04240-2020

Ejemplares similares